[1] RAJKUMAR S V, LANDGREN O, MATEOS M V. Smold-ering multiple myeloma [J]. Blood, 2015, 125(20): 3069-3075.
[2] RAJKUMAR S V, DIMOPOULOS M A, PALUMBO A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma [J]. Lancet Oncol, 2014, 15(12): e538-e548.
[3] PAWLYN C, MORGAN G J. Evolutionary biology of high-risk multiple myeloma [J]. Nat Rev Cancer, 2017, 17(9): 543-556.
[4] KYLE R A, REMSTEIN E D, THERNEAU T M, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma [J]. N Engl J Med, 2007, 356(25): 2582-2590.
[5] LAKSHMAN A, RAJKUMAR S V, BUADI F K, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria [J]. Blood Cancer J, 2018, 8(6): 59.
[6] MANN H, KATIYAR V, VARGA C, et al. Smoldering multiple myeloma - past, present, and future [J]. Blood Rev, 2022, 52: 100869.
[7] CHOJNACKA M, DIAMOND B, LANDGREN O, et al. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions [J]. Semin Oncol, 2022, 49(1): 11-18.
[8] DUTTA A K, ALBERGE J B, SKLAVENITIS-PISTOFIDIS R, et al. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine [J]. Nat Rev Clin Oncol, 2022, 19(4): 223-236.
[9] LOPEZ-CORRAL L, GUTIERREZ N C, VIDRIALES M B, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells [J]. Clin Cancer Res, 2011, 17(7): 1692-1700.
[10] RAJKUMAR S V, GUPTA V, FONSECA R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma [J]. Leukemia, 2013, 27(8): 1738-1744.
[11] MERZ M, HIELSCHER T, SCHULT D, et al. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma [J]. Leukemia, 2020, 34(4): 1192-1196.
[12] OLIVA S, DE PAOLI L, RUGGERI M, et al. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma [J]. Ann Hematol, 2021, 100(2): 437-443.
[13] DONG L, CHEN C Y, NING B, et al. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma [J]. Genet Mol Res, 2015, 14(3): 9571-9584.
[14] YU C Y, XIANG S, HUANG Z, et al. Gene co-expression network and copy number variation analyses identify transcription factors associated with multiple myeloma progression [J]. Front Genet, 2019, 10: 468.
[15] BARRIO GARCIA S, RUIZ-HEREDIA Y, DA VIA' M, et al. Role of MAX as a tumor suppressor driver gene in multiple myeloma [J]. Blood, 2017, 130(Supplement 1): 4347.
[16] BOTTA C, DI MARTINO M T, CILIBERTO D, et al. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival [J]. Blood Cancer J, 2016, 6(12): e511.
[17] KHAN R, DHODAPKAR M, ROSENTHAL A, et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120) [J]. Haematologica, 2015, 100(9): 1214-1221.
[18] BOLLI N, BIANCON G, MOARII M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups [J]. Leukemia, 2018, 32(12): 2604-2616.
[19] LIONETTI M, DA VIA M C, ALBANO F, et al. Genomics of smoldering multiple myeloma: time for clinical translation of findings? [J]. Cancers: Basel, 2021, 13(13):3319.
[20] BOLLI N, MAURA F, MINVIELLE S, et al. Genomic patterns of progression in smoldering multiple myeloma [J]. Nat Commun, 2018, 9(1): 3363.
[21] BUSTOROS M, SKLAVENITIS-PISTOFIDIS R, PARK J, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression [J]. J Clin Oncol, 2020, 38(21): 2380-2389.
[22] DUTTA A K, FINK J L, GRADY J P, et al. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability [J]. Leukemia, 2019, 33(2): 457-468.
[23] BUSTOROS M, ANAND S, SKLAVENITIS-PISTOFIDIS R, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes [J]. Nat Commun, 2022, 13(1): 3449.
[24] BOYLE E M, DESHPANDE S, TYTARENKO R, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma [J]. Nat Commun, 2021, 12(1): 293.
[25] WALKER B A, BOYLE E M, WARDELL C P, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma [J]. J Clin Oncol, 2015, 33(33): 3911-3920.
[26] MAILANKODY S, KAZANDJIAN D, KORDE N, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma [J]. Blood Adv, 2017, 1(22): 1911-1918.
[27] MISUND K, KEANE N, STEIN C K, et al. MYC dysregulation in the progression of multiple myeloma [J]. Leukemia, 2020, 34(1): 322-326.
[28] OBEN B, FROYEN G, MACLACHLAN K H, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities [J]. Nat Commun, 2021, 12(1): 1861.
[29] HO M, GOH C Y, PATEL A, et al. Role of the bone marrow milieu in multiple myeloma progression and therapeutic resistance [J]. Clin Lymphoma Myeloma Leuk, 2020, 20(10): e752-e768.
[30] GARCIA-ORTIZ A, RODRIGUEZ-GARCIA Y, ENCINAS J, et al. The role of tumor microenvironment in multiple myeloma development and progression [J]. Cancers: Basel, 2021, 13(2):217.
[31] ISOLA I, BRASO-MARISTANY F, MORENO D F, et al. Gene expression analysis of the bone marrow microenvironment reveals distinct immunotypes in smoldering multiple myeloma associated to progression to symptomatic disease [J]. Front Immunol, 2021, 12: 792609.
[32] ZAVIDIJ O, HARADHVALA N J, MOUHIEDDINE T H, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma [J]. Nat Cancer, 2020, 1(5): 493-506.
[33] PAIVA B, MATEOS M V, SANCHEZ-ABARCA L I, et al. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis [J]. Blood, 2016, 127(9): 1151-1162.
[34] FERNANDEZ N, PERUMAL D, RAHMAN A, et al. High dimensional immune profiling of smoldering multiple myeloma distinguishes distinct tumor microenvironments [J]. Clin Lymphoma Myeloma Leuk, 2022, 22(11):853-862. |
